Preston Romm Joins Suneva Medical As Chief Operating Officer

SAN DIEGO, June 16, 2016 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, today announced the appointment of Preston Romm to chief operating officer (COO). Romm joins Suneva Medical with more than 30 years of experience and will be responsible for leading the company's sales, marketing and operations. Previously serving as president of Obagi Medical Products and senior vice president of Valeant Pharmaceuticals, Romm brings a rich background in the facial aesthetic industry and will be an instrumental executive on Suneva Medical's leadership team.

"Preston's impressive track record and deep rooted experience in facial aesthetics is a welcomed addition," said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer at Suneva Medical. "As we enter another significant growth phase at Suneva, he will play a critical role in further elevating our position as an innovative aesthetics player that is committed to exceptional results and enduring patient satisfaction."

Romm's decades of senior leadership experience spans finance, marketing, sales, operations and administration. Throughout his career, he has been responsible for overseeing financing growth strategies, negotiating and integrating mergers and acquisitions, supply chain management processes, ERP systems, internal controls and Sarbanes-Oxley compliance procedures. Romm holds an MBA from American University and a B.S. in Accounting from the University of Maryland.

"Joining Suneva is a tremendous opportunity and I look forward to advancing its position within the general dermatology and aesthetic markets," said Romm. "In a short time, the company has built a strong business foundation and it will be my top priority to strengthen opportunities within its operations, sales and marketing teams."

For more information on Suneva Medical, visit www.sunevamedical.com.

About Suneva Medical, Inc.

Suneva Medical is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. The company markets Bellafill® in the U.S., Canada and Hong Kong; ArteFill® in South Korea; Regenica® skin care in the U.S., Canada and Hong Kong; and ReFissa® tretinoin cream in the U.S. ArteFill® was rebranded to Bellafill® in the U.S. to reflect the transformational outcomes this unique product can provide to patients seeking correction of their acne scars and nasolabial folds. For more information, visit www.sunevamedical.com.

Logo - http://photos.prnewswire.com/prnh/20150227/178494LOGO

SOURCE Suneva Medical, Inc.

Related Links

http://www.sunevamedical.com